Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 572

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 572
---
 Capital. The promissory note is non-interest bearing and matures on May 4, 2025.

On November 15, 2024, the Company issued a $100,000 promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on May 15, 2025.

On November 20, 2024, the Company issued a $100,000 promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on May 20, 2025.

On December 13, 2024, the Company issued a
$50,000 promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on June 13, 2025.

On January 8, 2025, the Company issued a $100,000
promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on July 8, 2025.

On January 17, 2025, the Company issued a
$100,000 promissory note to FutureTech Capital. The promissory note is non-interest bearing and matures on July 17, 2025.

| F-50 |

<div align='center'>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

To the Shareholders and Board of Directors of

Longevity Biomedical, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets
of Longevity Biomedical, Inc. (the “Company”) as of December 31, 2023 and 2022, the related statements of operations, changes
in shareholders’ deficit and cash flows for each of the two years in the period ended December 31, 2023, and the related notes
(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its
cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted
in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant
working